SWX:IDIABiotechs
Idorsia (SWX:IDIA) Stock Price Hinges On QUVIVIQ Growth And Funding Risk
Idorsia closed at CHF6.12, roughly flat over the past week but still carrying a strong 90 day rebound in the share price. The market has been treating this as a recovery story. The Q2 earnings headline pulls investors back to the balance sheet. The company is still loss making and carries negative shareholders’ equity, and yet trades on a price to sales ratio of 7.8x, below both the European biotech average and key peers. The central question now is whether the liquidity moves and earnings...